U.S. markets closed

Ipsen S.A. (IPN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
68.80-0.70 (-1.01%)
At close: 5:35PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close69.50
Open68.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range68.55 - 69.60
52 Week Range34.20 - 95.90
Volume175,781
Avg. Volume119,944
Market Cap5.691B
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.59
Earnings DateFeb 11, 2021 - Feb 15, 2021
Forward Dividend & Yield1.00 (1.39%)
Ex-Dividend DateJun 03, 2020
1y Target Est144.23
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • BETTERLIFE PHARMA ANNOUNCES CLOSING OF $2.9 MILLION PRIVATE PLACEMENT OFFERING
      GlobeNewswire

      BETTERLIFE PHARMA ANNOUNCES CLOSING OF $2.9 MILLION PRIVATE PLACEMENT OFFERING

      NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATESVANCOUVER, BC, Dec. 02, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT), an emerging biotech company, is pleased to announce that it has closed its previously announced private placement offering of special warrants of the Company (the “Special Warrants”), pursuant to which the Company issued  5,889,735 Special Warrants at a price of $0.50 per Special Warrant, for aggregate gross proceeds of $2,944,867.50 (the “Offering”). The Offering was led by Mackie Research Capital Corporation as lead agent and sole bookrunner (the “Lead Agent”), on behalf of a syndicate, including Haywood Securities Inc. (collectively, the “Agents”). Each Special Warrant is exercisable, for no additional consideration, into one unit of the Company (each, a “Unit”), with each Unit consisting of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share (each, a “Warrant Share”) at an exercise price of $0.60 per Warrant Share, for a period of 36 months after the closing of the Offering (the “Closing”).All unexercised Special Warrants will automatically be exercised on the day (the “Qualification Date”) that is the earlier of (i) four (4) months and a day following the Closing, and (ii) as soon as reasonably practicable, and in any event no later than the third (3rd) Business Day, after a receipt is issued for the Final Prospectus qualifying the distribution of the Units underlying the Special Warrants and the Units underlying the Compensation Options (as defined below) granted to the Agents (the “Compensation Option Units”).The net proceeds raised under the Offering will be used for working capital and general corporate purposes.The Company will use its reasonable commercial efforts to prepare and file with each of the securities regulatory authorities in each of the provinces of Canada, except Quebec, in which the of Special Warrants are sold (the “Jurisdictions”) and obtain a receipt for, a preliminary short form prospectus and a final short form prospectus (the “Final Prospectus”), qualifying the distribution of the Units underlying the Special Warrants and the Compensation Option Units, in compliance with applicable securities law, within forty (40) days from the Closing. In the event that the Company has not received a receipt for the Final Prospectus within forty (40) days following the Closing, each unexercised Special Warrant will thereafter entitle the holder thereof to receive upon the exercise thereof, at no additional consideration, one-and-one-tenth (1.10) Unit (instead of one Unit) and thereafter at the end of each additional thirty (30) day period prior to the Qualification Date, each Special Warrant will be exercisable for an additional 0.02 of a Unit.The Company will use commercial reasonable efforts to obtain the necessary approvals to list the Common Shares, the Warrant Shares and Common Shares issuable on the exercise of the Compensation Option Units on the Canadian Securities Exchange on the Qualification Date and the date of the issuance of the underlying Warrant Shares following the Qualification Date, respectively.In connection with the Offering, the Agents received an aggregate cash fee equal to 8.0% of the gross proceeds from the Offering. In addition, the Company granted to the Agents on Closing non-transferable compensation options (the “Compensation Options”) equal to 8.0% of the total number of Special Warrants sold under the Offering. Each Compensation Option entitles the holder thereof to purchase one Compensation Option Unit at an exercise price of $0.50 for a period of 36 months following Closing.About BetterLife Pharma Inc.BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferonbased technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.For further information please visit www.blifetherapeutics.com.Contact Information:Ahmad Doroudian, Chief Executive Officer Email: Ahmad.Doroudian@blifepharma.com Phone: 604-221-0595 Dost Mustaq, BDA International Investor Relations Contact Email: ir@blifepharma.com Phone: 646-679-4321The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSNo Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

    • Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook
      Business Wire

      Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook

      Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook

    • GlobeNewswire

      What do the Pfizer Vaccine and BetterLife Pharma have in common?

      New York City, Nov. 18, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotech company focused on development and commercialization of interferon (IFN) based therapeutics, recently provided a clinical and regulatory update for its AP-003 COVID-19 clinical trials using inhaled interferon alpha 2b.  While recent advancements in vaccines may seem to provide a glimmer of hope for bringing the pandemic to a close, it remains to be seen how safe and effective they will be, and for how long. The importance of life-saving COVID-19 therapeutics is as great ever, and the support for the Company’s use of interferon as a therapeutic for COVID-19 is compelling. Recent research, summed up by an article from NBC which stated ‘’COVID-19 patients with life-threatening illness have antibodies that disable key immune system proteins called interferons’’, highlighted the latest findings on the importance of interferon and its role in fighting Covid-19  and other viral infections:      ·Crucial Role of IFNs in Virus Infections Type I IFNs are our natural first line of defence against ANY and ALL viruses. The human body has a non-specific surveillance system in all its cells, since any cell can be infected - that detects virus and immediately triggers a response in that cell.  This is true whether it is a respiratory virus targeting the airways and lungs (flu and coronaviruses), a virus that targets the liver (hepatitis B or C), the heart (Coxsackie virus), the gut (many enteric viruses), the brain (Zika), or whether the virus enters the skin through a mosquito bite (dengue, West Nile virus).That immediate sensing of a virus leads immediately to the production of interferons - regardless of the virus. This is true for ALL viruses. This IFN response is highly important as some intelligent viruses have evolved to have specific genes that block this IFN response.  because viruses have co-evolved to very specifically have genes that will block this IFN response.   According to Dr. Eleanor Fish, an expert on IFNs and member of the Scientific board for BetterLife, SARS-COV-2 (the virus responsible for COVID-19) has within its viral genome a number of such trigger genes that are turned on immediately after the virus infects cells in the hosts airways which in turn produces factors that block IFN production.      ·Role of IFN (or lack thereof) in COVID-19In the high profile publication referenced above, it was shown that not only does SARS CoV-2 blunt/diminish an IFN response, thereby disabling an effective immune response to this infection, but that those individuals who become infected that have low blood levels of IFN tend to experience a more severe illness.  Similarly, those individuals who have any mutations in genes associated with the IFN response also tend to have a more severe response to COVID-19.  Individuals who, for whatever reason, have antibodies to IFN, will also elicit a more severe COVID.   All this informs us of the importance of the IFN response in resolving COVID.       ·Pfizer Vaccine: an IFN Cell ModulatorThe importance of IFN response has also been reflected in the development of the Pfizer vaccine.  The vaccine stimulates the production of IFN gamma in T Cells (responsible for fighting infections).  IFN gamma is Type II IFN.  Both Type I (the Company’s interferon alpha 2b) and type II interferons (are central to both combating virus infection and modulating the antiviral immune response.      ·An inhalation form of IFN based product can play an important role in fighting MOST infections beyond COVID-19.               For every vaccine or drug that targets a specific aspect of a virus, viruses mutate and become drug resistant. Not so for IFNs: IFNs are produced by the immune system and are not virus-specific, thus there is no development of resistance to IFNs.Notably, IFN targets many different stages of the virus life cycle - from blocking entry into cells, to preventing uncaring of enveloped viruses, to degrading the virus genome, to blocking the assembly of the virus particle and prevent virus form getting out of cells. When cells have a huge number of virus particles, IFN will kill the cell - and the virus. IFN will also recruit specific immune cells to a site of infection, and activate them to clear the infection. The Company has always maintained that the best approach to deal with virus infections are combination therapies, incorporating a cocktail of drugs that target different aspects of the virus.  Dr. Ahmad Doroudian, CEO BetterLife , has mentioned in recent interviews that the best approach may well be combining IFN with remdesivir and/or the monoclonal antibodies being evaluated now.Affordable treatments will always be important.  Remdesivir and monoclonal antibodies are very expensive and additionally are injected, not administered into the airways where the virus resides.Dr. Doroudian  believes that that an inhaled IFN such as the Company’s AP-003 therapeutic that directly targets the airways and that is also affordable will have widespread utility for COVID-19 and any other respiratory infection that might appear in the future. While millions of people around the World may well have access to a vaccine eventually, there will be hundreds of thousands for whom the vaccine may well not work and will require effective treatment options.   AP-003 as both a treatment and preventative may well provide the solution for this unmet need, following conclusion of its imminent trials in Australia.About BDA International, Inc.: BDA International is an independent global firm offering a wide range of IR and PR related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including BETRF. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and BETRF may do so via the contact information at the bottom of this release.Disclaimer The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. BetterLife Pharma is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.Investor Relations Contact: Dost Mushtaq                                                                       BDA International     www.bda-ir.com dost@bda-ir.com